GleamWall
中文EN

ARDX ARDELYX, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1437402 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.6%
TTM net income YoY1.9%
TTM EPS YoY0.0%
Revenue 3-yr CAGR51.6%
Net income 3-yr CAGR—

Margins

Gross margin94.5%
Operating margin-7.7%
Net margin-11.8%
FCF margin-3.4%
EBITDA margin-7.1%

Returns

ROE-34.9%
ROA-10.3%
ROIC (approx.)-8.3%
Asset turnover0.87x

Leverage & solvency

Liabilities / assets72.1%
Debt / equity1.54x
Current ratio3.45x
Interest coverage-1.63x

Cash quality & payout

Operating cash flow / net income0.28x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$407.32M$333.62M
Cost of revenue$39.54M$50.56M
Gross profit$367.78M$283.06M
R&D expense$71.53M$52.32M
SG&A expense$337.23M$258.69M
Operating income-$40.98M-$27.95M
Interest expense$20.10M$13.01M
Pretax income-$60.63M-$38.87M
Income tax$969,000$266,000
Net income-$61.60M-$39.14M
EBITDA-$37.92M-$25.89M
EPS (basic)-0.26-0.17
EPS (diluted)-0.26-0.17
Weighted avg. shares (diluted)241.03M235.23M
Balance sheet
Cash & equivalents$68.00M$64.93M
Short-term investments$196.69M$185.17M
Receivables$71.85M$57.70M
Inventory$123.11M$91.18M
Current assets$382.32M$356.45M
PP&E, net$2.18M$1.50M
Total assets$501.60M$435.75M
Current liabilities$88.61M$77.83M
Long-term debt$202.83M$150.85M
Total debt$202.83M$150.85M
Total liabilities$334.65M$262.46M
Shareholders' equity$166.95M$173.29M
Net debt$134.84M$85.92M
Shares outstanding244.35M238.02M
Cash flow statement
Operating cash flow-$42.48M-$44.81M
Capital expenditure$1.49M$1.01M
Free cash flow-$43.98M-$45.82M
Investing cash flow-$8.96M-$18.32M
Financing cash flow$54.51M$106.59M
Depreciation & amortization$3.06M$2.06M
Stock-based compensation$48.96M$37.38M

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.